ANGPTL Inhibitor

Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.

Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

Anti-ANGPTL4 Antibody is a CHO expressed human antibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).

Zodasiran (ARO-ANG3) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

Zodasiran sodium (ARO-ANG3 sodium) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran sodium can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

Cy3 labled Zodasiran sodium is a Cy3 (HY-D0822) labled Zodasiran sodium (HY-177671A). Zodasiran sodium (ARO-ANG3 sodium) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran sodium can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia.

Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

Corveldebart is a monoclonal antibody of immunoglobulin G1-kappa that targets ANGPTL4. Corveldebart can be used as an immunomodulator.

Solbinsiran sodium (LY3561774 sodium) is a GalNAc-conjugated siRNA targeting ANGPTL3. Solbinsiran sodium mediates RNA interference against hepatic ANGPTL3 mRNA, reducing ANGPTL3 translation. Solbinsiran sodium lowers hepatocyte ANGPTL3 mRNA and serum ANGPTL3 protein levels. Solbinsiran sodium can be used in research on mixed dyslipidemia.

Lexosiran is a siRNA that inhibits ANGPTL3 (angiopoietin-related protein 3) synthesis, and can be use for the study of antihyperlipidaemic.

Zodasiran sodium scrambled negative control is the sequence scrambled negative control of Zodasiran sodium (HY-177671A). Zodasiran sodium (ARO-ANG3 sodium) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran sodium can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

Solbinsiran sodium scrambled negative control is the sequence scrambled negative control of Solbinsiran sodium.

Lexosiran sodium is a siRNA that inhibits ANGPTL3 angiopoietin-related protein 3 synthesis, and can be use for the study of antihyperlipidaemic.

Solbinsiran (LY3561774) is a GalNAc-conjugated siRNA targeting ANGPTL3. Solbinsiran mediates RNA interference against hepatic ANGPTL3 mRNA, reducing ANGPTL3 translation. Solbinsiran lowers hepatocyte ANGPTL3 mRNA and serum ANGPTL3 protein levels. Solbinsiran can be used in research on mixed dyslipidemia.

FAM labled Zodasiran sodiumis a FAM labled Zodasiran sodium (HY-177671A). Zodasiran sodium (ARO-ANG3 sodium) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran sodium can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

Vupanorsen sodium scrambled negative control is the sequence scrambled negative control of Vupanorsen sodium.

Anti-ANGPTL8 Antibody is a CHO expressed human antibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).